Table 1 Relationship between miR-1-3p and clinicopathologic variables in patients with prostate cancer
Variables | miR-1-3p | P value | ||
|---|---|---|---|---|
All cases | Low expression | High expression | ||
(n = 124) | (n = 54) | (n = 70) | ||
Age | ||||
  ≥ 65y | 70 | 30 (42.9%) | 40 (57.1%) | 0.860 |
  < 65y | 54 | 24 (44.4%) | 30 (55.6%) | |
Serum PSA | ||||
  ≥ 10 ng/ml | 74 | 35 (47.3%) | 39 (52.7%) | 0.306 |
  < 10 ng/ml | 50 | 19 (38.0%) | 31 (62.0%) | |
Gleason score | ||||
  ≥ 7 | 76 | 42 (55.3%) | 34 (44.7%) | 0.001 |
  < 7 | 48 | 12 (25.0%) | 36 (76.0%) | |
pT stage | ||||
  < T3 | 35 | 23 (65.7%) | 12 (34.3%) | 0.002 |
  ≥ T3 | 89 | 31 (34.8%) | 58 (65.2%) | |
Lymph node metastasis | ||||
 Presence | 31 | 20 (64.5%) | 11 (35.5%) | 0.012 |
 Absence | 93 | 34 (36.6%) | 59 (63.4%) | |
Seminal vesicle invasion | ||||
 Presence | 33 | 19 (57.6%) | 14 (42.4%) | 0.164 |
 Absence | 81 | 35 (43.2%) | 46 (56.8%) | |
Biochemical recurrence | ||||
 Presence | 14 | 9 (64.3%) | 5 (35.7%) | 0.097 |
 Absence | 110 | 45 (40.9%) | 65 (59.1%) | |